Ladenburg Thalmann Downgrades XTL Biopharmaceuticals (XTLB) to Sell
XTLB Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 2 | New: 1
Ladenburg Thalmann downgrades XTL Biopharmaceuticals (Nasdaq: XTLB) from Buy to Sell.
XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of diabetic neuropathic pain and hepatitis C.
XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of diabetic neuropathic pain and hepatitis C.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- BMO Capital on NetApp (NTAP): Could Attract Interested Parties At These Levels; Prefers EMC
- Canaccord Genuity Downgrades Mercer International (MERC) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Ladenburg Thalmann Financial ServicesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
